RecruitingNot ApplicableNCT07816809

Phage-based Control and Limitation of Pathobionts for Microbiome Equilibrium and Resilience

Phage-CLEAR: Phage-based Control and Limitation of Pathobionts for Microbiome Equilibrium and Resilience


Sponsor

Colorado State University

Enrollment

40 participants

Start Date

Sep 14, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

Bacteriophages are viruses that can selectively infect specific species and strains of bacteria. Some bacterial species in the human gut have been negatively associated with gut health and skin health. This study is designed to measure the efficacy of two different bacteriophage-based treatments for 4 weeks to improve gut and skin health. These treatments are bacteriophage that target specific strains of Escherichia coli and Staphylococcus Aureus.


Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Bacteriophages - MuniPhage, Bacteriophages - RenuPhage, and others for people with gastrointestinal symptoms and skin quality. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIETARY_SUPPLEMENTBacteriophages - MuniPhage

1 x 106 Plaque Forming Units (PFU) of bacteriophage strains PBH34, CAH57, BFX121, and DNK95

DIETARY_SUPPLEMENTBacteriophages - RenuPhage

1 x 106 PFU of phage strains LG91, BD117, CD007, and PD23

OTHERPlacebo

Rice maltodextrin


Locations(1)

Colorado State University

Fort Collins, Colorado, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07816809


Related Trials